Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it compare to its competitors? We will compare Aethlon Medical to related companies based on the strength of its dividends, earnings, risk, institutional ownership, profitability, valuation and analyst recommendations.
Valuation and Earnings
This table compares Aethlon Medical and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aethlon Medical||$150,000.00||-$5.67 million||-2.37|
|Aethlon Medical Competitors||$1.08 billion||$109.59 million||25.11|
Aethlon Medical’s competitors have higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Aethlon Medical has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Aethlon Medical’s competitors have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.
Institutional & Insider Ownership
7.0% of Aethlon Medical shares are held by institutional investors. Comparatively, 60.0% of shares of all “Analytical instruments” companies are held by institutional investors. 6.6% of Aethlon Medical shares are held by company insiders. Comparatively, 14.6% of shares of all “Analytical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings for Aethlon Medical and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aethlon Medical Competitors||116||736||1090||51||2.54|
Aethlon Medical currently has a consensus target price of $3.00, suggesting a potential upside of 175.23%. As a group, “Analytical instruments” companies have a potential upside of 7.07%. Given Aethlon Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Aethlon Medical is more favorable than its competitors.
This table compares Aethlon Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aethlon Medical Competitors||-190.83%||-33.65%||-15.46%|
Aethlon Medical competitors beat Aethlon Medical on 8 of the 13 factors compared.
Aethlon Medical Company Profile
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.